|
WO2020205576A1
|
|
Anti-axl antibodies and methods of use thereof
|
|
WO2020181080A1
|
|
Biomarkers for treatment of cancer
|
|
WO2020123444A1
|
|
Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
|
|
WO2020106461A2
|
|
Anti-mertk antibodies and methods of use thereof
|
|
KR20210011919A
|
|
Anti-CD27 antibody and anti-PD-L1 antibody and bispecific construct
|
|
US2021077832A1
|
|
Methods of treating cancer with dendritic cell mobilizing agents
|
|
WO2019084307A1
|
|
Anti-mertk antibodies and methods of use thereof
|
|
EP3445783A2
|
|
Agonistic antibodies that bind human cd40 and uses thereof
|
|
EP3341021A2
|
|
Anti-alk antibodies and methods for use thereof
|
|
AU2016216524A1
|
|
Antibodies that bind human CD27 and uses thereof
|
|
EP3283111A1
|
|
Biomarkers related to treatment of cancer with her3 and egfr inhibitors
|
|
US2018044429A1
|
|
Cd27 agonists
|
|
EP3191128A1
|
|
Uses of anti-her3 antibodies for treating cancer
|
|
AU2015215852A1
|
|
Vaccine compositions
|
|
US2014314780A1
|
|
Compositions Using Antibodies Directed to GPNMB and Uses Thereof
|
|
AU2013205381A1
|
|
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
|
AU2013203270A1
|
|
Antibodies that bind human CD27 and uses thereof
|
|
AU2013201417A1
|
|
Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
|
|
EP3763740A1
|
|
Anti-kit antibodies and uses thereof
|
|
CA2815237A1
|
|
Method of improving transplant function using soluble complement receptor type i (scr1)
|
